• CLCC1 and Herpesvirus Nuclear Egress

  2026-10-08

  A 2024 bioRxiv preprint identifies CLCC1 as a host factor required for the membrane-fusion stage of herpes simplex virus 1 nuclear egress. The findings connect CLCC1 loss with perinuclear vesicle accumulation, impaired nuclear pore complex insertion, and reduced viral output, while also highlighting important limits because the study was not yet peer reviewed.

• Dutasteride: Evidence and Research Context

  2026-10-08

  Dutasteride is a dual 5-alpha-reductase inhibitor studied in androgen-dependent prostate models, while the supplied liver study addresses a separate Arrb2–6-ketoLCA pathway in hepatic ischemia–reperfusion injury. This overview separates supplier-reported findings from peer-reviewed evidence, compares model relevance, and defines the limits of cross-domain interpretation.

• Nilotinib Research Context: Evidence and Limits

  2026-10-07

  Nilotinib, also known as AMN-107, is best established as a clinically used kinase inhibitor in BCR-ABL-driven disease. This overview compares its oncology rationale with emerging neurodegeneration research, emphasizing what the 2024 Alzheimer’s disease study found, what remains uncertain, and where evidence cannot yet support broader therapeutic conclusions.

• 5-EdU for Developmental Birth Dating

  2026-10-07

  5-EdU provides a sensitive route to S phase DNA synthesis detection, but its greatest value depends on how labeling is interpreted. This article examines 5-Ethynyl-2'-deoxyuridine through the lens of rat claustrum development, emphasizing evidence boundaries, spatial patterning, and study design rather than protocol execution.

• U-73122 and the Translational Logic of PLC Signaling

  2026-10-06

  U-73122 is most valuable when treated as one layer in a triangulated strategy for studying PLC signaling, tumor invasion, calcium dynamics, and inflammation. This analysis connects the QPRT–myosin light chain axis to phospholipase C while defining evidence strength, selectivity limits, and translational boundaries.

• RNA Pol II Degradation and Apoptotic Signaling

  2026-10-06

  Harper et al. show that inhibition of RNA polymerase II can trigger apoptosis through active sensing of depleted hypophosphorylated RNA Pol IIA, rather than through transcriptional collapse alone. The study defines a Pol II degradation-dependent apoptotic response and provides a framework for interpreting how transcription-targeting drugs and other anticancer agents may engage regulated cell death.

• Mifepristone (RU486) and Hormone-Targeted Translation

  2026-10-05

  Mifepristone (RU486) offers translational researchers a defined way to interrogate progesterone receptor biology across oncology and reproductive science. This article connects its reported mechanisms with a broader lesson from prostate cancer research: receptor heterogeneity can determine therapeutic response, making biomarker context as important as compound selection.

• Thymoquinone and Doxorubicin Cardiotoxicity

  2026-10-05

  A 2025 mouse study reports that thymoquinone reduced doxorubicin-associated cardiac injury while improving antioxidant and ferroptosis-related readouts. Its main contribution is the integration of cardiac function, redox biomarkers, pathway proteins, tissue staining, and mitochondrial ultrastructure, although the findings remain preclinical and do not establish clinical efficacy or definitive pathway causality.

• FGFR3 Inhibition in SLC26A2 Chondrodysplasia

  2026-10-04

  A 2024 Journal of Orthopaedic Translation study used genetic mouse models, inducible postnatal deletion, chondrocyte assays, and pharmacological intervention to test whether excessive FGFR3 signaling contributes to SLC26A2-related chondrodysplasia. The results support FGFR3 pathway inhibition as a mechanistically plausible strategy for improving cartilage development and skeletal microarchitecture in mice, while leaving important questions about human translation unresolved.

• CKI 7 Dihydrochloride: CK1 Research Context

  2026-10-03

  CKI 7 dihydrochloride is a supplier-described Casein kinase 1 inhibitor used as a research tool for examining phosphorylation-dependent signaling. This overview separates that product information from a recent NSCLC study of the MAPK10/KRT16/RNF213 axis and explains why the two subjects should not be treated as mechanistically interchangeable.

• Erlotinib and SCUBE3: Mapping EGFR Resistance

  2026-10-02

  SCUBE3 research reframes EGFR biology as a network problem involving oncogenic signaling, therapy resistance, DNA repair, and immune suppression. This thought-leadership guide explains how Erlotinib can serve as a mechanistic probe for EGFR dependence while outlining a translational strategy that distinguishes direct pathway inhibition from SCUBE3-associated adaptation.

• Cryoablation, Tregs, and TGF-β in Lung Adenocarcinoma

  2026-10-01

  Lin et al. integrate single-cell and bulk transcriptomics with prospective immune monitoring and cryoablation models to show that cryoablation reshapes the lung adenocarcinoma microenvironment through TGF-β-associated regulation of Tregs. The findings connect reduced TGF-β1–Smad signaling and FOXP3 expression with stronger IFN-γ-associated antitumor immunity, while also defining important limits for translating the mechanism into clinical studies.

• Nuclear mTORC1 Control Revealed by TerminaTOR

  2026-10-01

  The reference study introduces TerminaTOR, a genetically encodable inhibitor that selectively perturbs mTORC1 in defined subcellular compartments. Its results distinguish lysosomal mTORC1 activity, which supports canonical nutrient signaling and autophagy control, from nuclear mTORC1 activity, which regulates transcription of CCAAT motif-containing genes.

• (Z)-4-Hydroxytamoxifen Workflow Guide

  2026-09-30

  Build more interpretable estrogen receptor experiments with high-affinity (Z)-4-Hydroxytamoxifen, from solvent handling and dose design to orthogonal pathway validation. The workflow also translates delivery, retention, and genetic-control lessons from a cartilage nanoparticle study into practical assay decisions without conflating disease models.

• MAPK10–KRT16 Axis in NSCLC Metastasis

  2026-09-30

  The reference study identifies MAPK10 as a suppressor of non-small cell lung cancer metastasis by promoting phosphorylation-dependent RNF213 ubiquitination and proteasomal degradation of KRT16. Its integrated cellular, animal, and clinical evidence defines a MAPK10/KRT16/RNF213 axis with potential value for biomarker development and mechanistic cancer research.

8146 records 1/544 page Next 12345 下5页 Last page